Insights

Insights From Our Experts

Articles

Product Master Data Management

This white paper shares considerations, common pitfalls and key takeaways for manufacturers participating in Medicaid. Recent market and enforcement trends in healthcare further exemplify the transition from a volume to value-based marketplace, as well as the complexities…

Precision Medicine Meets Precision Patient Support

In the value-driven healthcare environment, orphan drug manufacturers are becoming increasingly aware that improving adherence requires a new approach to patient understanding and support. Take for example the required lifestyle, nutritional or physical modifications often necessary…

Biosimilar Pricing in Europe

This report titled Biosimilar Pricing in Europe is published by Pricentric, by EVERSANA. It examines the pricing and pricing trends of biosimilar drugs in the US and EU5. It particularly looks at the pricing of Infliximab…

Wearables In Clinical Trials

Pharma Voice Magazine features Sandra Shpilberg from Seeker Health, an EVERSANA company, in their March 2019 issue. The topic is “Wearables in Clinical Trial”.  The article discusses how wearables are improving the clinical trial experience for patients…

The Brink of the Biosimilar Revolution

Although biosimilars have not had the immediate uptake in the United States that they have had in Europe, health plans expect these products will become a staple of therapy for some diseases by 2020—if the price…

MedicarePartD
Medicare Part D: Closing the Coverage Gap

Signed into law on February 9, 2018, the Bipartisan Budget Act (BBA) of 2018 entails significant adjustments to consumer spending under the Medicare Part D prescription drug program. Beginning in 2019, the period of out-of-pocket expenses…

The Radical Implications Of Indication-Specific Pricing

This paper discusses one of the potentially more impactful new dynamics in the pricing of pharmaceuticals—the advent of indication-specific pricing. Our goal is to provide context to this important change, highlight some of the implications about…

Don’t Poke The Bear: The Effect Of Pharmaceutical Pricing On Perception And Future Innovation

Companies like Turing Pharmaceuticals and KV Pharmaceuticals have grabbed headlines recently for their aggressive pricing strategies. Whether these strategies are justified or even successful is not the point. Rather, what is important is the negative public …